14,760 Shares in Harrow Health, Inc. (NASDAQ:HROW) Bought by Walleye Capital LLC

Walleye Capital LLC acquired a new position in Harrow Health, Inc. (NASDAQ:HROWGet Rating) during the second quarter, Holdings Channel reports. The firm acquired 14,760 shares of the company’s stock, valued at approximately $107,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Stansberry Asset Management LLC increased its stake in Harrow Health by 7.5% in the first quarter. Stansberry Asset Management LLC now owns 143,756 shares of the company’s stock valued at $981,000 after acquiring an additional 10,017 shares during the last quarter. Equitable Trust Co. bought a new position in Harrow Health in the second quarter valued at $407,000. Bailard Inc. increased its stake in Harrow Health by 9.9% in the second quarter. Bailard Inc. now owns 16,837 shares of the company’s stock valued at $123,000 after acquiring an additional 1,515 shares during the last quarter. Westside Investment Management Inc. increased its stake in Harrow Health by 11.3% in the second quarter. Westside Investment Management Inc. now owns 197,664 shares of the company’s stock valued at $10,269,000 after acquiring an additional 20,144 shares during the last quarter. Finally, Envestnet Asset Management Inc. bought a new position in Harrow Health in the first quarter valued at $70,000. Hedge funds and other institutional investors own 59.83% of the company’s stock.

Harrow Health Stock Up 1.7 %

Shares of NASDAQ:HROW opened at $10.47 on Monday. The stock’s 50-day moving average price is $10.97 and its 200-day moving average price is $8.59. Harrow Health, Inc. has a 12-month low of $5.40 and a 12-month high of $13.29. The stock has a market capitalization of $283.42 million, a P/E ratio of -12.61 and a beta of 0.41. The company has a current ratio of 3.49, a quick ratio of 4.61 and a debt-to-equity ratio of 83.80.

Analyst Upgrades and Downgrades

Separately, B. Riley started coverage on Harrow Health in a research note on Thursday, September 8th. They issued a “buy” rating and a $17.00 target price on the stock.

Insider Activity

In other news, Director Richard L. Md Lindstrom sold 40,000 shares of the firm’s stock in a transaction dated Friday, September 30th. The stock was sold at an average price of $12.62, for a total transaction of $504,800.00. Following the transaction, the director now directly owns 26,100 shares of the company’s stock, valued at $329,382. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Richard L. Md Lindstrom sold 40,000 shares of the stock in a transaction dated Friday, September 30th. The shares were sold at an average price of $12.62, for a total transaction of $504,800.00. Following the completion of the sale, the director now directly owns 26,100 shares in the company, valued at $329,382. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Opaleye Management Inc. bought 11,085 shares of the company’s stock in a transaction dated Wednesday, September 28th. The shares were purchased at an average price of $9.77 per share, with a total value of $108,300.45. Following the completion of the acquisition, the insider now owns 3,185,000 shares of the company’s stock, valued at approximately $31,117,450. The disclosure for this purchase can be found here. Insiders own 14.26% of the company’s stock.

About Harrow Health

(Get Rating)

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.

Featured Articles

Want to see what other hedge funds are holding HROW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harrow Health, Inc. (NASDAQ:HROWGet Rating).

Institutional Ownership by Quarter for Harrow Health (NASDAQ:HROW)

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.